Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M104,570Revenue (TTM) $M25,638Net Margin (%)23.2Altman Z-Score2.1
Enterprise Value $M134,989EPS (TTM) $3.6Operating Margin %36.6Piotroski F-Score6
P/E(ttm)18.1Beneish M-Score-2.4Pre-tax Margin (%)30.8Higher ROA y-yN
Price/Book23.010-y EBITDA Growth Rate %--Quick Ratio1.5Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %9.5Current Ratio1.7Lower Leverage y-yY
Price/Free Cash Flow16.3y-y EBITDA Growth Rate %23.9ROA % (ttm)9.7Higher Current Ratio y-yY
Dividend Yield %3.6PEG1.9ROE % (ttm)117Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M1,594ROIC % (ttm)21.9Gross Margin Increase y-yN

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ABBV is held by these investors:



ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Michael Robert A.VP, Controller 2017-03-10Sell5,132$65.290.55view
Schumacher Laura JExecutive Vice President 2017-03-10Sell40,000$65.260.6view
RICHMOND TIMOTHY J.SVP, Human Resources 2017-03-10Sell22,451$65.290.55view
GONZALEZ RICHARD AChairman of the Board and CEO 2017-03-08Sell72,016$64.252.18view
HURWICH THOMAS A.VP, Controller 2017-02-28Sell2,311$61.896.08view
CHASE WILLIAM JEVP, CFO 2016-12-02Sell6,600$59.1910.91view
HURWICH THOMAS A.VP, Controller 2016-11-16Sell3,100$625.89view
Schumacher Laura JExecutive Vice President 2016-09-07Sell50,000$651view
Schumacher Laura JExecutive Vice President 2016-06-24Sell186,106$60.039.36view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-06-02Sell285,953$63.822.87view

Press Releases about ABBV :

Quarterly/Annual Reports about ABBV:

News about ABBV:

Articles On GuruFocus.com
Galapagos Begins Cystis Fibrosis Treatment Study Mar 22 2017 
AbbVie's Hepatitis C Treatment Under Priority Review in Japan Mar 15 2017 
Goldman Sachs Upgrades AbbVie to Conviction-Buy Mar 13 2017 
Small-Caps and Pharma Are Where This Billionaire Is Investing Mar 08 2017 
Results of Johnson & Johnson's Psoriasis Clinical Trials Impressive Mar 08 2017 
AAA Credit Rating Stocks in Focus: Johnson & Johnson Mar 07 2017 
TG Therapeutics Surges 85% on Results From Study Mar 06 2017 
AbbVie Regimen Recommended for HCV Infection Feb 28 2017 
Aytu BioScience May Lead the Way in Low T Feb 28 2017 
Pfizer Reports Top-Line Results For Rheumatoid Arthritis Treatment Study Feb 27 2017 

More From Other Websites
Amgen's (AMGN) Humira Biosimilar Receives Approval in EU Mar 24 2017
Bernie Sanders thinks this $89,000-a-year drug should be $1,000 a year Mar 24 2017
Julianne Hough Empowers Women to "Get in the Know" About Endometriosis Mar 23 2017
[$$] Rare Discovery: A Value in the Biotech World Mar 22 2017
Galapagos Begins Cystis Fibrosis Treatment Study Mar 22 2017
AbbVie upgraded by Societe Generale Mar 22 2017
[$$] Rare Discovery: A Value in the Biotech World Mar 22 2017
Blog Coverage Eli Lilly Announced Positive Results from Breast Cancer Drug Combination Study Mar 22 2017
Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks Mar 21 2017
[$$] New Enterprise Associates Joins SetPoint Medical Syndicate Mar 20 2017
Update in Lawsuit for Investors in NYSE: ABBV Shares Against AbbVie Inc. Announced by Shareholders... Mar 20 2017
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data Mar 16 2017
AbbVie's Hepatitis C Treatment Under Priority Review in Japan Mar 15 2017
AbbVie Receives An Upgrade From Vetr Mar 14 2017
AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir... Mar 14 2017
Goldman Sachs Adds AbbVie to Conviction List Mar 13 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)